Formats:

• Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume
• Results in less than 3 hours
• Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Lymphocyte-activation gene 3 (LAG-3), also known as CD223, is a cell surface protein that affects T-cell function in many ways. LAG-3 is expressed on natural killer cells, plasmacytoid dendritic cells, B-cells, and activated T-cells. LAG-3 works in similar fashion to CTLA-4 and PD-1 in that it negatively regulates cellular proliferation and Treg suppression. Maturation and activation of dendritic cells is also known to be affected by LAG-3 expression. Soluble forms are in clinical development to activate dendritic cells. Anti-LAG-3 antibodies are undergoing studies for anti-cancer and autoimmune response.